To print this article, all you need is to be registered or login on Mondaq.com.
As announced in the Budget speech 2021-2022, the Government of
Mauritius took the first step in the setting up of the Mauritius
Institute of Biotechnology Ltd (“MIBL”) with a seed
capital of around USD 25 million. Initially starting as a project
to comply with the recommendations of the World Health Organisation
(“WHO”) with regard to COVID-19 vaccine demand, the
2022-2023 Budget Speech extended the mandate of the MIBL beyond
vaccine manufacturing by banking on the competitive edge of
Mauritius in the pharmaceutical sector.
In this respect, the primary stakeholders of the Mauritius
Pharmaceutical industry are inviting interested partners willing to
contribute to the structuring of a Hi-Tech Pharmaceutical Industry
in Mauritius. Find more details on the objectives of the industry,
the competitive edge of Mauritius and the application process in
the official communiqué issued by the EDB HERE.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from Mauritius